Independent. No tobacco money. No corporate fluff.MON, AUG 17

PouchDaily

The daily pulse of the nicotine pouch market

PMI's $1.2 billion ZYN megafactory opens in Colorado

Philip Morris International has opened a $1.2 billion ZYN manufacturing campus in Aurora, Colorado — its largest US facility and the biggest bet yet on nicotine pouch production. The 780,000-square-foot plant employs 500 people and began commercial output in July 2026.

PouchDaily Desk·

Philip Morris International just placed the biggest manufacturing bet in nicotine pouch history. On 27 July 2026 the company officially opened a $1.2 billion ZYN manufacturing campus in Aurora, Colorado — its first greenfield factory in the United States and its largest facility dedicated entirely to ZYN nicotine pouches.

The 780,000-square-foot plant on a 148-acre site began commercial production in July 2026 and is expected to employ around 500 workers at average salaries of roughly $90,000. PMI estimates the campus will generate about $550 million in annual economic impact for Colorado, plus around 1,000 indirect jobs.

What happened

The Aurora campus is PMI's first manufacturing complex built from the ground up in the US. The company originally announced the project in 2024 as a $600 million investment; it has since doubled to a planned $1.2 billion between 2024 and 2028, with approximately $1 billion already spent. The Haskell Company delivered the design-build project in 19 months.

The facility integrates production, packaging, warehousing, and distribution under one roof. It joins PMI's existing US manufacturing network — facilities in Owensboro, Kentucky and Wilson, North Carolina — and is positioned as both a domestic supply hub and an export platform for regions including Asia and Latin America.

Stacey Kennedy, CEO of PMI U.S., said: "This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand in the United States and around the world."

Why it matters

The scale of this investment tells you where PMI thinks the pouch market is going. A $1.2 billion greenfield factory is not a hedge — it's a commitment to ZYN as a core growth engine, not a side category.

The timing sharpens the point. The Aurora opening came less than a month after the US Food and Drug Administration authorized 20 ZYN nicotine pouch products as Modified Risk Tobacco Products (MRTPs) — making ZYN the first pouch brand permitted to tell consumers it presents "a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis" compared to combustible cigarettes. That authorization gives ZYN a marketing advantage no competitor currently has, and PMI is now building the capacity to push it.

There's also a Colorado symmetry. ZYN was first introduced in the state in 2014 through a limited market test. Twelve years later, Colorado is home to the brand's largest production facility in the world.

The campus also marks a milestone in PMI's integration of Swedish Match, which it acquired in 2022 for $16 billion. ZYN was Swedish Match's flagship product; Aurora is the physical manifestation of PMI turning that acquisition into a US manufacturing base.

What's next

The factory is live but not finished. PMI has said the site will continue expanding with additional production capacity and infrastructure through 2028. The export dimension matters: if ZYN's international demand grows — particularly in markets where pouch regulation is still permissive — Aurora becomes the supply node.

The competitive landscape adds pressure. PMI's own Q2 2026 results showed ZYN's US growth slowing as Velo and on! PLUS gain share. A bigger factory doesn't automatically win the shelf, but it does give PMI the volume, cost structure, and supply reliability to compete on price and availability — the factors that decide which pouch brands survive consolidation.

For investors, the context is mixed. PMI's stock was up roughly 17% year to date as of early August 2026, but the company faces headwinds including a Brazil public health lawsuit and the broader pattern of rising sales but compressed net income. Aurora is a long-term capital commitment that will be judged against whether ZYN's volume trajectory justifies it.


SOURCES:


Compare ZYN prices across retailers at PouchFinder.